Overview

Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Status:
Completed

Trial end date:
2018-07-18

Target enrollment:

Participant gender:

Summary

This randomized phase 3 trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy. Radiation therapy in this study is regulatory medical care based on the patient's needs and the radiation oncologist's judgment. It is not possible nor necessary to explicitly define the dose or duration of treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Stanford University

Collaborator:

National Cancer Institute (NCI)

Treatments:

Eusol
Pharmaceutical Solutions
Sodium Hypochlorite